You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國中藥(00570.HK)急漲15%直逼百天線獲大摩升級至「增持」
阿思達克 08-23 14:08

中國中藥(00570.HK)獲大摩及大華繼顯分別升級至「增持」及「買入」均看4.5元,其中大摩料中國中藥2018-2021年盈利複合年均增長率達20.5%,認為公司目前盈利表現及增長前景與其股價嚴重脫節,相信市場會在未來12個月對此有所調整。該股今天突破50天線(3.58元)阻力後,升幅擴至15%,報3.92元,直逼百天線(3.97元),成交增至5,202萬股,涉資1.96億元。

該公司本周初公布,中期純利按年升13%至8.59億元人民幣(下同),每股盈利17.06分,中期股息按年減少逾5%至5.72港仙。期內,營業額按年增加27%至69.37億元;毛利按年升近43%至41.87億元,整體毛利率按年升6.7個百分點至60.4%。業績曝光後,瑞信維持中國中藥「跑贏大市」評級看4.81元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account